S-1 and the treatment of gastric cancer with peritoneal dissemination

  • Authors:
    • Kunihiko Izuishi
    • Reiji Haba
    • Yoshio Kushida
    • Kyuichi Kadota
    • Ryusuke Takebayashi
    • Takanori Sano
    • Hisashi Usuki
    • Mohammad Akram Hossain
    • Hirohito Mori
    • Tsutomu Masaki
    • Yasuyuki Suzuki
  • View Affiliations

  • Published online on: June 20, 2011     https://doi.org/10.3892/etm.2011.290
  • Pages: 985-990
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peritoneal dissemination is the most common metastatic pattern of gastric cancer. We frequently face the necessity for gastrectomy in the event of gastric stenosis or gastric bleeding. However, the indication for palliative gastrectomy and the effectiveness of palliative chemotherapy are not clear. We retrospectively evaluated the prognostic factors after palliative gastrectomy in 121 gastric cancer patients with peritoneal dissemination. The expression of orotate phosphoribosyl transferase (OPRT) was examined immunohistochemically. The median survival time of all patients after palliative gastrectomy was 8.8 months. In the multivariate analyses, we adjusted the data of 82 patients without liver metastases for the background of 5-fluouracil (5-FU)-based chemotherapy regimen. The analysis revealed that the degree of peritoneal dissemination (multiple vs. a few metastases or cytology-positive; P=0.01) and chemotherapy (S-1 vs. other 5-FU; P=0.01) were independent predictors of survival. Particularly, S-1 treatment was associated with a more favorable prognosis of the patients with high levels of OPRT expression compared to that of the patients with low expression. Patients with peritoneal dissemination are considered as terminal and inoperable. However, S-1 treatment may improve the survival after palliative gastrectomy in patients selected according to the degree of peritoneal dissemination and high OPRT expression.
View Figures
View References

Related Articles

Journal Cover

September-October 2011
Volume 2 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Izuishi K, Haba R, Kushida Y, Kadota K, Takebayashi R, Sano T, Usuki H, Hossain MA, Mori H, Masaki T, Masaki T, et al: S-1 and the treatment of gastric cancer with peritoneal dissemination. Exp Ther Med 2: 985-990, 2011
APA
Izuishi, K., Haba, R., Kushida, Y., Kadota, K., Takebayashi, R., Sano, T. ... Suzuki, Y. (2011). S-1 and the treatment of gastric cancer with peritoneal dissemination. Experimental and Therapeutic Medicine, 2, 985-990. https://doi.org/10.3892/etm.2011.290
MLA
Izuishi, K., Haba, R., Kushida, Y., Kadota, K., Takebayashi, R., Sano, T., Usuki, H., Hossain, M. A., Mori, H., Masaki, T., Suzuki, Y."S-1 and the treatment of gastric cancer with peritoneal dissemination". Experimental and Therapeutic Medicine 2.5 (2011): 985-990.
Chicago
Izuishi, K., Haba, R., Kushida, Y., Kadota, K., Takebayashi, R., Sano, T., Usuki, H., Hossain, M. A., Mori, H., Masaki, T., Suzuki, Y."S-1 and the treatment of gastric cancer with peritoneal dissemination". Experimental and Therapeutic Medicine 2, no. 5 (2011): 985-990. https://doi.org/10.3892/etm.2011.290